CAPTRUST Financial Advisors
EIGR

CAPTRUST Financial Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

CAPTRUST Financial Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2
Closed – – 5200
2021
Q4 		$0 Hold
2
– – ﹤0.01% 4966
2021
Q3 		$0 Hold
2
– – ﹤0.01% 4804
2021
Q2 		$0 Hold
2
– – ﹤0.01% 4694
2021
Q1 		$0 Buy
+2
New +$630 ﹤0.01% 4504

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAPTRUST Financial Advisors's EIGR Position: Q1 2022 in Review

CAPTRUST Financial Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2022, closing a stake of 2 shares.

CAPTRUST Financial Advisors first reported a position in EIGR in Q1 2021 and held it in 4 quarters. The position peaked at $0 in Q4 2021. 94 funds tracked by Wall St. Rank hold EIGR as of Q1 2022.

  • CAPTRUST Financial Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 2 Eiger BioPharmaceuticals, Inc. shares in Q1 2022.
  • CAPTRUST Financial Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2021 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $0 in Q4 2021.
  • 94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2022, filed 16 May 2022.